MedTrace Logo

Mifepristone 2.5, 5, 10 mg Versus Placebo in the Treatment of Endometriosis

NCT02271958 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2014-10-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness and safety of 2.5, 5 and 10 mg doses of mifepristone against a placebo in women with laparoscopic diagnostic of endometriosis.

The hypothesis of the study is that the 5 mg mifepristone dose is safe and effective and should be used in future studies on medical treatment of endometriosis.

Conditions

  • Endometriosis

Interventions

DRUG

Mifepristone

DRUG

PLACEBO

Sponsors & Collaborators

  • Mediterranea Medica S. L.

    lead OTHER

Principal Investigators

  • Josep Ll Carbonell, Doctor · Medical Clinic Mediterranea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-10-31
Completion
2013-12-31

Countries

  • Cuba

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02271958 on ClinicalTrials.gov